<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570476</url>
  </required_header>
  <id_info>
    <org_study_id>9985</org_study_id>
    <secondary_id>NCI-2018-00977</secondary_id>
    <secondary_id>9985</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1718008</secondary_id>
    <nct_id>NCT03570476</nct_id>
  </id_info>
  <brief_title>Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer</brief_title>
  <official_title>Open-Label, Pilot Study of Olaparib as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well olaparib works in treating participants with prostate&#xD;
      cancer that has not spread to other parts of the body (localized). Olaparib may stop the&#xD;
      growth of tumor cells by interfering with the activity of a substance called PARP, which is&#xD;
      inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount&#xD;
      of normal tissue that needs to be removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the pathological complete response rate following olaparib when administered as&#xD;
      neoadjuvant therapy prior to prostatectomy in patients with localized prostate cancer&#xD;
      containing homozygous or complementary deoxyribonucleic acid [DNA] repair deficiency.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the rate of positive surgical margins, extracapsular extension, positive&#xD;
      seminal vesicles and lymph nodes at the time of prostatectomy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable&#xD;
      toxicity. Beginning 1 day after last olaparib dose, participants undergo radical&#xD;
      prostatectomy.&#xD;
&#xD;
      After completion of study treatment, participants are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response (pCR) Rate</measure>
    <time_frame>At time of prostatectomy (at 12 weeks)</time_frame>
    <description>Percent of patients who achieve a pCR at the time of prostatectomy, after 12 weeks of neoadjuvant therapy with olaparib. PCR is defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen. Assessment will be based on the recommendations of the International Society of Urological Pathology (ISUP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to 30 days after the last dose of olaparib</time_frame>
    <description>Will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Positive Surgical Margins</measure>
    <time_frame>At time of prostatectomy (at 12 weeks)</time_frame>
    <description>The rate of detectable tumor in pathology specimens obtained at prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage of Disease</measure>
    <time_frame>At time of prostatectomy (at 12 weeks)</time_frame>
    <description>Pathology specimens obtained at prostatectomy will be assessed using the tumor, lymph node, and metastasis (TNM) staging system for prostate cancer.&#xD;
Stage Stage 2 represents patients with disease without evidence of extension outside of the prostate Stage 3 represents patients with disease which has penetrated the capsule of the prostate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Prostate Adenocarcinoma Without Neuroendocrine Differentiation</condition>
  <condition>Stage I Prostate Cancer AJCC v8</condition>
  <condition>Stage II Prostate Cancer AJCC v8</condition>
  <condition>Stage IIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIC Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (olaparib, radical prostatectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (olaparib, radical prostatectomy)</arm_group_label>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
    <other_name>Lynparza</other_name>
    <other_name>PARP Inhibitor AZD2281</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Prostatectomy</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Treatment (olaparib, radical prostatectomy)</arm_group_label>
    <other_name>Prostatovesiculectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures.&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate without morphologic&#xD;
             neuroendocrine differentiation or small cell features.&#xD;
&#xD;
          -  The presence of homologous recombination deficiency defined by either; A) Inherited&#xD;
             pathogenic variant of BRCA2, ATM, BRCA1, PALB2 by a Clinical Laboratory Improvement&#xD;
             Act (CLIA) level germline assay or B) have evidence by somatic sequencing using a CLIA&#xD;
             level assay of biallelic inactivation of BRCA1, BRCA2, PALB2, FANCA or biallelic&#xD;
             inactivation or monoallelic inactivating mutation of ATM. It is anticipated that the&#xD;
             majority of patients will be germline carriers of a pathogenic variant of BRCA1, BRCA2&#xD;
             or ATM. Other germline mutations will be considered at investigator's discretion.&#xD;
&#xD;
          -  Must be candidates for radical prostatectomy and considered surgically resectable by&#xD;
             urologic evaluation.&#xD;
&#xD;
          -  No evidence of metastatic disease or nodal disease as determined by radionuclide bone&#xD;
             scans and computed tomography (CT)/magnetic resonance imaging (MRI); non-pathological&#xD;
             lymph nodes must be less than 20 mm in the short (transverse) axis.&#xD;
&#xD;
          -  Provided written authorization for use and release of health and research study&#xD;
             information.&#xD;
&#xD;
          -  Hemoglobin &gt;= 10.0 g/dL with no blood transfusion in the past 28 days.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L (within 28 days prior to&#xD;
             administration of study treatment).&#xD;
&#xD;
          -  Platelet count &gt;= 100 x 10^9/L (within 28 days prior to administration of study&#xD;
             treatment).&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN) (within 28 days&#xD;
             prior to administration of study treatment).&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) /&#xD;
             alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =&lt; 2.5 x&#xD;
             institutional upper limit of normal unless liver metastases are present in which case&#xD;
             they must be =&lt; 5 x ULN (within 28 days prior to administration of study treatment).&#xD;
&#xD;
          -  Patients must have creatinine clearance estimated using the Cockcroft-Gault equation&#xD;
             of &gt;= 51 mL/min (within 28 days prior to administration of study treatment).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          -  Patients must have a life expectancy &gt;= 16 weeks.&#xD;
&#xD;
          -  Male patients and their partners, who are sexually active and of childbearing&#xD;
             potential, must agree to the use of two highly effective forms of contraception in&#xD;
             combination throughout the period of taking study treatment and for 3 months after&#xD;
             last dose of study drug(s) to prevent pregnancy in a partner.&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site).&#xD;
&#xD;
          -  Any previous treatment with PARP inhibitor, including olaparib.&#xD;
&#xD;
          -  Other malignancy within the last 5 years except: adequately treated non-melanoma skin&#xD;
             cancer, or other solid tumors including lymphomas (without bone marrow involvement)&#xD;
             curatively treated with no evidence of disease for &gt;= 5 years.&#xD;
&#xD;
          -  Resting electrocardiogram (ECG) with corrected QT interval (QTc) &gt; 470 msec on 2 or&#xD;
             more time points within a 24-hour period or family history of long QT syndrome.&#xD;
&#xD;
          -  Patients receiving any systemic chemotherapy, hormonal therapy or radiotherapy.&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin,&#xD;
             clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,&#xD;
             saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g.&#xD;
             ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout&#xD;
             period prior to starting olaparib is 2 weeks.&#xD;
&#xD;
          -  Concomitant use of known strong (e.g. phenobarbital, phenytoin, rifampicin, rifabutin,&#xD;
             rifapentine, carbamazepine, nevirapine and St John's wort) or moderate CYP3A inducers&#xD;
             (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting&#xD;
             olaparib is 5 weeks for phenobarbital and 3 weeks for other agents.&#xD;
&#xD;
          -  Patients with myelodysplastic syndrome/acute myeloid leukemia or with features&#xD;
             suggestive of myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML).&#xD;
&#xD;
          -  Major surgery within 2 weeks of starting study treatment and patients must have&#xD;
             recovered from any effects of any major surgery.&#xD;
&#xD;
          -  Patients considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, non-malignant systemic disease or active, uncontrolled infection. Examples&#xD;
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3&#xD;
             months) myocardial infarction, uncontrolled major seizure disorder, extensive&#xD;
             interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan&#xD;
             or any psychiatric disorder that prohibits obtaining informed consent.&#xD;
&#xD;
          -  Patients unable to swallow orally administered medication and patients with&#xD;
             gastrointestinal disorders likely to interfere with absorption of the study&#xD;
             medication.&#xD;
&#xD;
          -  Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Patients with a known hypersensitivity to olaparib or any of the excipients of the&#xD;
             product.&#xD;
&#xD;
          -  Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of&#xD;
             transmitting the infection through blood or other body fluids.&#xD;
&#xD;
          -  Previous allogenic bone marrow transplant or cord blood transplantation.&#xD;
&#xD;
          -  Whole blood transfusions in the last 120 days prior to entry to the study (packed red&#xD;
             blood cells and platelet transfusions are acceptable).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Montgomery</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <results_first_submitted>August 7, 2020</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2020</results_first_posted>
  <disposition_first_submitted>July 6, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 1, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 21, 2020</disposition_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03570476/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03570476/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Olaparib, Radical Prostatectomy)</title>
          <description>Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.&#xD;
Olaparib: Given PO&#xD;
Radical Prostatectomy: Undergo surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Olaparib, Radical Prostatectomy)</title>
          <description>Participants receive olaparib PO BID for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.&#xD;
Olaparib: Given PO&#xD;
Radical Prostatectomy: Undergo surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response (pCR) Rate</title>
        <description>Percent of patients who achieve a pCR at the time of prostatectomy, after 12 weeks of neoadjuvant therapy with olaparib. PCR is defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen. Assessment will be based on the recommendations of the International Society of Urological Pathology (ISUP).</description>
        <time_frame>At time of prostatectomy (at 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Olaparib, Radical Prostatectomy)</title>
            <description>Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.&#xD;
Olaparib: Given PO&#xD;
Radical Prostatectomy: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response (pCR) Rate</title>
          <description>Percent of patients who achieve a pCR at the time of prostatectomy, after 12 weeks of neoadjuvant therapy with olaparib. PCR is defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen. Assessment will be based on the recommendations of the International Society of Urological Pathology (ISUP).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
        <time_frame>Up to 30 days after the last dose of olaparib</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Olaparib, Radical Prostatectomy)</title>
            <description>Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.&#xD;
Olaparib: Given PO&#xD;
Radical Prostatectomy: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Positive Surgical Margins</title>
        <description>The rate of detectable tumor in pathology specimens obtained at prostatectomy.</description>
        <time_frame>At time of prostatectomy (at 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Olaparib, Radical Prostatectomy)</title>
            <description>Participants receive olaparib PO BID for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.&#xD;
Olaparib: Given PO&#xD;
Radical Prostatectomy: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Positive Surgical Margins</title>
          <description>The rate of detectable tumor in pathology specimens obtained at prostatectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage of Disease</title>
        <description>Pathology specimens obtained at prostatectomy will be assessed using the tumor, lymph node, and metastasis (TNM) staging system for prostate cancer.&#xD;
Stage Stage 2 represents patients with disease without evidence of extension outside of the prostate Stage 3 represents patients with disease which has penetrated the capsule of the prostate</description>
        <time_frame>At time of prostatectomy (at 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Olaparib, Radical Prostatectomy)</title>
            <description>Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.&#xD;
Olaparib: Given PO&#xD;
Radical Prostatectomy: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Stage of Disease</title>
          <description>Pathology specimens obtained at prostatectomy will be assessed using the tumor, lymph node, and metastasis (TNM) staging system for prostate cancer.&#xD;
Stage Stage 2 represents patients with disease without evidence of extension outside of the prostate Stage 3 represents patients with disease which has penetrated the capsule of the prostate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>Adverse events were collected according to CTCAE version 5</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Olaparib, Radical Prostatectomy)</title>
          <description>Participants receive olaparib PO BID for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.&#xD;
Olaparib: Given PO&#xD;
Radical Prostatectomy: Undergo surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bruce Montgomery, PI</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-598-0860</phone>
      <email>rbmontgo@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

